Ind-Swift Laboratories has approved a capital investment of around Rs 40 crore to upgrade its finished dosage manufacturing facility located at Samba, Jammu & Kashmir. With this investment, the facility will be enhanced to meet international regulatory standards, primarily EU-GMP and PIC/S, enabling the site to cater to regulated export markets.
Proposed enhancements will improve environmental sustainability, strengthen material governance, and enhance utility reliability across the facility. The company assumes to complete this upgradation within a span of 8-12 months. Upon completion, the company envisages to receive EU GMP approval within 8-9 months & plans to simultaneously file around 15-20 molecules across Europe & UK, Australia, Canada and South Africa.
The existing ointment section is currently catering to the domestic market which includes manufacturing of own brands, contract manufacturing. Other dosage forms like tablets, capsules, dry syrups are also supplied from this facility. The unit generates an annual sales of Rs 36 crore with a bottom line of an average 10%.
Ind-Swift Laboratories is global manufacturer of APIs, Intermediates and formulations (through group collaboration).
